Eur Cell Mater. 2014 May 6;27:12-6. doi: 10.22203/ecm.v027sa03.
An AO Foundation (Davos, Switzerland) sponsored workshop "Cell Therapy in Cartilage Repair" from the Symposium "Where Science meets Clinics" (September 5-7, 2013, Davos) gathered leaders from medicine, science, industry, and regulatory organisations to debate the vision of cell therapy in articular cartilage repair and the measures that could be taken to narrow the gap between vision and current practice. Cell-based therapy is already in clinical use to enhance the repair of cartilage lesions, with procedures such as microfracture and articular chondrocyte implantation. However, even though long term follow up is good from a clinical perspective and some of the most rigorous randomised controlled trials in the regenerative medicine/orthopaedics field show beneficial effect, none of these options have proved successful in restoring the original articular cartilage structure and functionality in patients so far. With the remarkable recent advances in experimental research in cell biology (new sources for chondrocytes, stem cells), molecular biology (growth factors, genes), biomaterials, biomechanics, and translational science, a combined effort between scientists and clinicians with broad expertise may allow development of an improved cell therapy for cartilage repair. This position paper describes the current state of the art in the field to help define a procedure adapted to the clinical situation for upcoming translation in the patient.
AO 基金会(瑞士达沃斯)主办的研讨会“软骨修复中的细胞治疗”,是“科学与临床的碰撞”研讨会的一部分(2013 年 9 月 5 日至 7 日,达沃斯),聚集了来自医学、科学、工业和监管组织的领导者,就细胞治疗在关节软骨修复中的前景,以及缩小愿景与当前实践之间差距的措施进行了辩论。基于细胞的治疗已经在临床上用于增强软骨损伤的修复,例如微骨折和关节软骨细胞植入。然而,尽管从临床角度来看,长期随访情况良好,而且再生医学/骨科领域中一些最严格的随机对照试验显示出有益的效果,但到目前为止,这些方法都未能成功恢复患者的原始关节软骨结构和功能。随着细胞生物学(新的软骨细胞来源、干细胞)、分子生物学(生长因子、基因)、生物材料、生物力学和转化科学方面的实验研究取得显著进展,具有广泛专业知识的科学家和临床医生的共同努力可能会为软骨修复开发出更好的细胞治疗方法。本立场文件描述了该领域的现状,以帮助确定一种适合临床情况的方法,以便在患者中进行即将到来的转化。